Surgical correction of pulmonary artery aneurysm may provide resolution of coronary symptoms in affected individuals.Read more
Expression of miRNA-126 and miRNA-145 were associated with increased plaque necrolipidic tissue content.Read more
The availability of low-cost xeno-free reagents will speed up therapeutic stem cell research and allow patients to receive treatments of the expected high standards at lower costs.Read more
Dr. Felipe Couñago, Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society) Coordinator; Radiation Oncology Department, Hospital Universitario Quirónsalud Madrid; Hospital La Luz, Madrid; Universidad Europea de Madrid, Spain.
Dr. Juan Carlos Trujillo-Reyes, Thoracic Oncology Committee of the Spanish Society of Pneumology and Thoracic Surgery (SEPAR); Thoracic Surgery Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Dr. Antonio Calles, Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid, Spain
Recent advances in radiological imaging and genomic analysis are profoundly changing the way to manage lung cancer patients. Screening programs which couple lung cancer risk prediction models and low-dose computed tomography (LDCT) recently showed their effectiveness in the early diagnosis of lung tumors. In addition, the emerging field of radiomics is revolutionizing the approach to handle medical images, i.e., from a "simple" visual inspection to a high-throughput analysis of hundreds of quantitative features of images which can predict prognosis and therapy response. Yet, with the advent of next-generation sequencing (NGS) and the establishment of large genomic consortia, the whole mutational and transcriptomic profile of lung cancer has been unveiled and made publicly available via web services interfaces. This has tremendously accelerated the discovery of actionable mutations, as well as the identification of cancer biomarkers, which are pivotal for development of personalized targeted therapies. The essence of precision medicine is to achieve the goal of "individualized treatment" through genotyping of patients and targeted therapy. Recent advances in the field of novel anticancer agents prolong patients' survival and show a promising future. Tyrosine kinase inhibitors and immunotherapy for lung cancer are the two major areas undergoing rapid development. Advances in image navigation, radiation planning, and dose application have enabled successful introduction of SBRT as a treatment regimen for many primary tumors and oligometastatic disease. If surgery is not possible or the patient refuses surgery, it is always reasonable to consider SBRT. Despite the tremendous progress made in understanding lung tumour biology, advances in early diagnosis, multimodal therapy and deciphering molecular mechanisms of drug resistance, overall curative outcomes remain low, especially in metastatic disease. Nanotechnology, in particular nanoparticles (NPs), Big Data and Artificial Intelligence to progressively impact the way by which tumours are diagnosed and treated.
We welcome submissions of original research as well as review articles that address the new advances in the diagnosis and treatment of lung cancer. Potential topics include but are not limited to the following:
-Advanced molecular imaging
-Next-generation sequencing (NGS)
-Advances in surgery
-Advances in radiotherapy
-Big data and AI
Submission starting date: January 30, 2020
Submission deadline: September 30, 2020
Expected publication date: December 30, 2020
Please submit your paper along with a cover letter including the special issue title. Your paper will undergo a fair peer review and be published free of charge and immediately after acceptance and will be available to an international audience.
This special issue is seeking to promote clinical and translational research in the area of sport-related concussion to support practical applications of laboratory-based assessments in a clinical setting.
Too often our clinical partners are unable to properly interpret or use laboratory-based findings to enhance clinical practice and promote evidence-based medicine. This may lead to a gap in knowledge between the scientist and the clinician, which could influence patient outcomes or result in suboptimal management of clinical cases.
Thus, this special issue is soliciting articles that address this concern or demonstrate the clinical utility or practical application of laboratory assessments to inform, aid, or apply in a clinical setting. Pleasebefore December 19, 2019.
The editorial board is proud to announce that the National Library of Medicine has officially confirmed that the Journal of Clinical and Translational Research has been indexed in PubMed and PubMed Central. All papers previously accepted in JCTR have appeared online and can be retrieved. The editorial board is grateful to all who have contributed to this milestone, which includes our authors, our reviewers, and our editorial board members.
JCTR is publishing a special issue on negative results obtained in ex vivo and in vivo research as well as in clinical trials. This special issue is guest edited by(Associate Director of the Yale-Hastings Program in Ethics & Health Policy; Departments of Psychology and Philosophy, Yale University, New Haven, Connecticut, United States) and (Department of Surgery, Academic Medical Center, University of Amsterdam).
The focus of the special issue is not why it is important to publish negative data. Instead, JCTR is giving the advocacy an actual follow-up by publishing robust studies with negative findings.
Please read the collection.
JCTR has prepared output style files for both EndNote and Mendeley users. Please contact ourto get a copy and make reference formatting easier.
Following the success of the previous events, Oxford Global is co-organizing two prestigious congresses in Boston this October: the Both congresses will take place on 23-24th October 2018 in Boston.and the .
The conferences feature key presentations including:
Single Cell Optical Analyses for Drug Discovery, Including Immunomodulatory Therapies, Andrea Pomerantz, Novartis; The Spatial Environment And Single-Cell Analysis, Guo-Cheng Yuan, Dana-Farber Cancer Institute and Transcriptomic Analysis In Immunology & Cancer Research, Virginia Savova, Sanofi.
NGS-based clinical diagnostics for comprehensive genomics profiling and liquid biopsies in molecular pathology by Sabah Kadri; Live Analysis Of Illumina Sequence Data While The Sequencer Is Still Running by Bernhard Renard, Robert Koch Institute and Clinical And Informatic Approaches To Genomic Screening, Matthew Lebo, Director Bioinformatics and Assistant Professor Pathology, Brigham and Woman's Hospital.
Read more details about speakers and agenda.
For further information regarding the conference programme, prices and possible discounts, please contact Angela Fernandez Saez onor call +44 (0)1865 248 455.
Dr. John E. Lewis is the co-founder and CEO of Nurish.Me. He is also a past full-time Associate Professor in the Department of Psychiatry and Behavioral Sciences at the University of Miami Miller School of Medicine and now remains as a Voluntary Associate Professor. He is a diplomate, faculty member, and advisor of the Medical Wellness Association.
Dr. Lewis has been the principal investigator of multiple nutrition, dietary supplement, exercise training, and medical device studies in the last 2 decades. Much of his research has included investigating the effects of interventions on a wide variety of outcomes, including immune and cognitive functioning, inflammation, physical fitness, nutrient status, quality of life, and mental health, in healthy adults and in those with Alzheimer’s, HIV, diabetes, chronic pain, and GI disorders, among others. He has co-authored more than 170 peer-reviewed scientific articles, has mentored many undergraduate, graduate, and medical students in exercise, nutrition, and health promotion, and has been an invited speaker at multiple international and national conferences, including aon the results of his work in Alzheimer's for TEDxMiami.
Prof. dr. Stuart S. Winter is Chief Research Officer at Children's Minnesota Research Institute, Professor of Pediatrics, and former Vice Chair of Pediatric Research at University of New Mexico, United States. With certification by the American Board of Pediatrics from 1994 onward, he is a practicing pediatric hematologist/oncologist with 24 years of experience. Prof. dr. Winter's translational focus is primarily directed towards the biology and classification of acute lymphoblastic leukemia (ALL) and the conduct of pediatric clinical trials.
rovide promo code "JCTR-biocytogen" to Biocytogen and receive 5% discount for your next gene editing project.is a leading gene targeted animal and services supplier globally. Biocytogen provides a traditonal ESC/HR platform as well as a cutting-edge Extreme Genome Editing (EGE®) system. P
(MD, PhD, Delft, the Netherlands) and (Associate Director of the Yale-Hastings Program in Ethics and Health Policy at Yale University, United States) are promoted to associate editors of the journal.